[Advances in Diagnosis and Therapies of Immune-mediated Inner Ear Diseases]

Overview

Journal Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

Specialty Otorhinolaryngology

Date 2020 Aug 14

PMID 32791601

Authors

Haoran Wang

Dayong Wang

Qiuju Wang

Affiliations

Soon will be listed here.

Abstract

Immune-Mediated Inner Ear Diseases（IMIED） is one of the curable sensorineural hearing loss caused by abnormal immune response, which may be primary inner ear diseases or associated with systemic autoimmune diseases. Since the complex differential diagnosis and no reliable diagnostic tests, the early identification of IMIED was extremely tricky. The treatment still mainly depends on glucocorticoid, but as researchs move along, directing at different pathogenesis, more and more therapies have been proposed. This article reviews the diagnosis and different treatment methods of IMIED.

References

Bovo R, Aimoni C, Martini A . Immune-mediated inner ear disease. Acta Otolaryngol. 2006; 126(10):1012-21. DOI: 10.1080/00016480600606723. View

Mijovic T, Zeitouni A, Colmegna I . Autoimmune sensorineural hearing loss: the otology-rheumatology interface. Rheumatology (Oxford). 2013; 52(5):780-9. DOI: 10.1093/rheumatology/ket009. View

Lee J, Kim J, Bok J, Kim K, Choi J, Kim S . Identification of evidence for autoimmune pathology of bilateral sudden sensorineural hearing loss using proteomic analysis. Clin Immunol. 2017; 183:24-35. DOI: 10.1016/j.clim.2017.06.008. View

Vambutas A, Pathak S . AAO: Autoimmune and Autoinflammatory (Disease) in Otology: What is New in Immune-Mediated Hearing Loss. Laryngoscope Investig Otolaryngol. 2016; 1(5):110-115. PMC: 5113311. DOI: 10.1002/lio2.28. View

Tsirves G, Voulgari P, Pelechas E, Asimakopoulos A, Drosos A . Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol. 2019; 276(9):2419-2426. DOI: 10.1007/s00405-019-05487-5. View

Ciorba A, Corazzi V, Bianchini C, Aimoni C, Pelucchi S, Skarzynski P . Autoimmune inner ear disease (AIED): A diagnostic challenge. Int J Immunopathol Pharmacol. 2018; 32:2058738418808680. PMC: 6213300. DOI: 10.1177/2058738418808680. View

Rauch S . Clinical management of immune-mediated inner-ear disease. Ann N Y Acad Sci. 1998; 830:203-10. DOI: 10.1111/j.1749-6632.1997.tb51891.x. View

Matteson E, Choi H, Poe D, Wise C, Lowe V, McDonald T . Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005; 53(3):337-42. DOI: 10.1002/art.21179. View

Derebery M, Fisher L, Voelker C, Calzada A . An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. Otol Neurotol. 2014; 35(9):1515-21. DOI: 10.1097/MAO.0000000000000566. View

10.

Mata-Castro N, Gavilanes-Plasencia J, Ramirez-Camacho R, Garcia-Fernandez A, Garcia-Berrocal J . Azathioprine reduces the risk of audiometric relapse in immune-mediated hearing loss. Acta Otorrinolaringol Esp (Engl Ed). 2018; 69(5):260-267. DOI: 10.1016/j.otorri.2017.08.006. View

11.

Marsili M, Marzetti V, Lucantoni M, Lapergola G, Gattorno M, Chiarelli F . Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report. Ital J Pediatr. 2016; 42(1):81. PMC: 5011950. DOI: 10.1186/s13052-016-0291-2. View

12.

Heywood R, Hadavi S, Donnelly S, Patel N . Infliximab for autoimmune inner ear disease: case report and literature review. J Laryngol Otol. 2013; 127(11):1145-7. DOI: 10.1017/S002221511300217X. View

13.

Aftab S, Semaan M, Murray G, Megerian C . Cochlear implantation outcomes in patients with autoimmune and immune-mediated inner ear disease. Otol Neurotol. 2010; 31(8):1337-42. DOI: 10.1097/MAO.0b013e3181f0c699. View

14.

Ralli M, DAguanno V, Stadio A, De Virgilio A, Croce A, Longo L . Audiovestibular Symptoms in Systemic Autoimmune Diseases. J Immunol Res. 2018; 2018:5798103. PMC: 6120292. DOI: 10.1155/2018/5798103. View

15.

Peneda J, Lima N, Monteiro F, Silva J, Gama R, Conde A . Immune-Mediated Inner Ear Disease: Diagnostic and therapeutic approaches. Acta Otorrinolaringol Esp (Engl Ed). 2018; 70(2):97-104. DOI: 10.1016/j.otorri.2017.08.008. View

16.

Pathak S, Goldofsky E, Vivas E, Bonagura V, Vambutas A . IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011; 186(3):1870-9. PMC: 3031454. DOI: 10.4049/jimmunol.1002275. View

17.

Goodall A, Siddiq M . Current understanding of the pathogenesis of autoimmune inner ear disease: a review. Clin Otolaryngol. 2015; 40(5):412-9. DOI: 10.1111/coa.12432. View

18.

Loveman D, de Comarmond C, Cepero R, Baldwin D . Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin Arthritis Rheum. 2004; 34(2):538-43. DOI: 10.1016/j.semarthrit.2003.10.002. View

19.

van Wijk F, Staecker H, Keithley E, Lefebvre P . Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol. 2006; 11(6):357-65. DOI: 10.1159/000095897. View

20.

Gazeau P, Saraux A, Devauchelle-Pensec V, Cornec D . Long-term efficacy of infliximab in autoimmune sensorineural hearing loss associated with rheumatoid arthritis. Rheumatology (Oxford). 2014; 53(9):1715-6. DOI: 10.1093/rheumatology/keu025. View